Anti-Human IL-2R alpha (CD25) (Basiliximab) – Dylight® 488

Home/Recombinant Antibodies/Biosimilar Recombinant Antibodies/Anti-Human IL-2R alpha (CD25) (Basiliximab) – Dylight® 488

Pricing & Details

Product No.LT311
Clone
Hu107
Protein
CD25
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
IL-2-RA; IL2-RA; TAC antigen; p55; CD25
Isotype
Human IgG1κ
Applications
FC
,
IF
,
IHC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT311-100 ug
100 µg
$325.00
Made to Order
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Human/Rhesus Monkey/Cynomolgus Monkey
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
Human CD25
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
Next Day 2-8°C
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
IF
IHC
Additional Reported Applications For Relevant Conjugates ?
CyTOF®
WB
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only.
Antigen Distribution
IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes.
Background
CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok